Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Abstract Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up p...
Saved in:
Main Authors: | Yuru Nie (Author), Weiqing Lu (Author), Daiyu Chen (Author), Huilin Tu (Author), Zhenling Guo (Author), Xuan Zhou (Author), Meifang Li (Author), Sanfang Tu (Author), Yuhua Li (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report
by: Ze-Fa Liu, et al.
Published: (2020) -
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018) -
Lower proportion of CD19+IL-10+ and CD19+CD24+CD27+ but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
by: Karolina Stożek, et al.
Published: (2020) -
CD19+CD24hiCD38hi B Cell Dysfunction in Primary Biliary Cholangitis
by: Qubo Chen, et al.
Published: (2020) -
Identification of Stem-Like Cells in Atrial Myxoma by Markers CD44, CD19, and CD45
by: Xianghe Song, et al.
Published: (2016)